Welcome to our new website! Please reset your password before logging in. Need help? Contact us: customer.service@sfihealth.com

Quick Links
cart icon 0
Author: SFI Health
  • Lifestyle insight
  • Reading Time: 1 Minute
SFI Health

Range Overview References

We invite you to explore the research references from our range overview.

References:

  1. Bianco L, et al. Pilot randomized controlled dosing study of cranberry capsules for reduction of bacteriuria plus pyuria in female nursing home residents. JAGS. 2012; 60(6):1180-1.
  2. Howell AB, et al. Dosage effect on uropathogenic Escherichia coli antiadhesion activity in urine following consumption of cranberry powder standardized for proanthocyanidin content: a multicentric randomized double blind study. BMC Infect Dis. 2010;10(1):94.
  3. Botto H, et al. Effectiveness of a cranberry (Vaccinium macrocarpon) preparation in reducing asymptomatic bacteriuria in patients with an ileal enterocystoplasty. Scand J Urol Nephrol. 2010;44(3):165-168.
  4. Lavigne J, et al. In-vitro and in-vivo evidence of dose-dependent decrease of uropathogenic Escherichia coli virulence after consumption of commercial Vaccinium macrocarpon (cranberry) capsules. Clin Microbiol Infect. 2008;14:350-355.
  5. Uberos J, et al. Cranberry syrup vs trimethoprim in the prophylaxis of recurrent urinary tract infections among children: a controlled trial. Open Access J Clin Trials 2012;4:31-386.
  6. Schellenberg R, et al. Dose-dependent effects of the Cimicifuga racemosa extract Ze 450 in the treatment of climacteric complaints: a randomized, placebo-controlled study. Evid Based Complement Alternat Med. 2012;(1):article ID 2603101.
  7. Drewe J, et al. The effect of a Cimicifuga racemosa extract Ze 450 in the treatment of climacteric complaints – an observational study. Phytomedicine. 2013;15(20):659–666.
  8. Lopatka L, et al. Black cohosh in the treatment of menopausal symptoms-results of an observational study with Cimifemin® uno (English translation) J für Menopause. 2007;2:3-7.
  9. Wesnes KA, et al. The cognitive, subjective, and physical effects of a Ginkgo biloba/Panax ginseng combination in healthy volunteers with neurasthenic complaints. Psychopharmacol Bull. 1997;33(4):677-683.
  10. Wesnes KA, et al. The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacology. 2000:152(4):353-361.
  11. Scholey AB, et al. Acute, dose-dependent cognitive effects of Ginkgo biloba, Panax ginseng and their combination in healthy young volunteers: differential interactions with cognitive demand. Hum Psychopharmacol Clin Exp. 2002;17:35-44.
  12. Reay JL, et al. Single doses of Panax ginseng (G115) reduce blood glucose levels and improve cognitive performance during sustained mental activity. Journal of
  13. Kiesewetter H, et al. Hemorrheological and circulatory effects of Gincosan. Int J Clin Pharmacol Ther Toxicol. 1992;30(3):97-102.
  14. Forgo I, et al. The duration of effect of the standardized ginseng extract G115 in healthy competitive athletes. Notabene Med. 1985;15(9):636-40.
  15. Forgo I, et al. On the question of influencing the performance of top sportsmen by means of biologically active substances. Aerztl Prax. 1981;33(44):1784-1786.
  16. Forgo I, et al. Effect of a standardized ginseng extract on general well-being, reaction capacity, pulmonary function and gonadal hormones. Med Welt. 1981;32(19):751-756.
  17. Rosenfeld M, et al. Evaluation of the efficacy of a standardized ginseng extract in patients with psychophysical asthenia and neurological disorders. La Semana Medica. 1989;173(9);148-154.
  18. Scaglione F, et al. Efficacy and safety of the standardized Ginseng extract G115 for potentiating vaccination against the influenza syndrome and protection against the common cold. Drugs Exp Clin Res.1996; 1996;22 (2):65-72.
  19. Reay JL, et al. Single doses of Panax ginseng (G115) reduce blood glucose levels and improve cognitive performance during sustained mental activity’ J Psychopharmacol. 2005;19(4):357-365.
  20. WHO Monographs on Selected Medicinal Plants, Volume 1, Geneva, World Health Organization, 1999, 154-167 (1999) [S01 -0599].
  21. Ginseng: ginseng radix. European Pharmacopoeia 5.1.2005, 2935-2936. 9. Ginseng radix: ginseng. ESCOP Monographs: the Scientific Foundation for Herbal Medicinal Products, 2nd Edition, Exeter, ESCOP, 2003; 211-222 [S05-0651].
  22. Radix ginseng. WHO monographs on medicinal plants commonly used in the Newly Independent States (NIS). Geneva: World Health Organization, 141-159 (2010).
  23. Ginseng root. The Expanded Commission E Monographs, American Botanical Council 2000. Available from https://cms.herbalgram.org/expandedE/Ginsengroot.html.
  24. Stough C, et al. The chronic effects of an extract of Bacopa monnieri (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology. 2001:156(4);481–484.
  25. Stough C, et al. Examining the nootropic effects of a special extract of Bacopa monnieri on human cognitive functioning: 90 day double-blind placebo-controlled randomized trial. Phytother Res. 2008;22(12):1629-1634.
  26. Downey L, et al. An acute, double-blind, placebo-controlled crossover study of 320 mg and 640 mg doses of a special extract of Bacopa monnieri (CDRI 08) on sustained cognitive performance. Phytother Res. 2013;27(9):1407-13.
  27. Benson S, et al. An acute, double-blind, placebo-controlled cross-over study of 320 mg and 640 mg doses of Bacopa monnieri (CDRI 08) on multitasking stress reactivity and mood. Phytother Res. 2014;28(4):551-9.
  28. Singh.HK. The Memory-Enhancing and Associated Effects of a Bacosides-Enriched Standardized Extract of Bacopa monniera (BESEB—CDRI-08). In Stough C. & Scholey A. (Eds.) 2013. Advances in Natural Medicines, Nutraceuticals and Neurocognition. Boca Raton: CRC Press, https://doi.org/10.1201/b13736.
  29. WHO monographs on selected medicinal plants Volume 2, Geneva, World Health Organization.
  30. Dehmlow C, et al. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology. 1996;23(4):749-54.
  31. Trappoliere M, et al. Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. Journal of hepatology. 2009;50(6):1102-11.
  32. Velussi M, et al. Long-term (23 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. Journal of hepatology. 1997;26(4):871-9.
  33. Schuppan D, Strosser W, Burkard G, Walosek G, 1998, Legalon® lessens fibrosing activity in patients with chronic liver diseases, Zeitschrift furAllgemeinmedizin, vol. 74, pp. 577-584.
  34. Albrecht, Frerick H, Kuhn U, Strenge-Hesse, 1992, The Treatment of Toxic Liver Damage with Legalon®, Clinical Pharmacology, vol. 47, no. 2, pp. 87-92.
  35. Buturova LI, Tsibizova TA 2010, Kalinin AV, Potential for the use of Legalon® in non-alcoholic fatty liver disease, Experimental and Clinical Gastroenterology, no. 3, pp. 85-91.
  36. Zhong S, Fan Y, Yan Q, Fan X, Wu B, et al. 2017, The Therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease: A meta-analysis (PRISMA) of randomized control trials, Medicine (Baltimore), vol. 96, no. 49, pp 1-7.
  37. Hashemi SJ, Hajiani E, Sardabi EH 2009, A Placebo-Controlled Trial of Silymarin in Patients with Nonalcoholic Fatty Liver Disease, Hepatitis Monthly, vol. 9, no. 4, pp. 265-270.
  38. Muzes G, Deak G, Lang I, Nekam K, Niederland V & Feher J 1990, Effects of Silybum (Legalon®) Treatment on the Antioxidant Defence System and Lipid Peroxidation in Patients with Chronic Alcohol Liver disease (A Double-Blind Study), Orvosi Hetilap,vol. 131, no. 16.
  39. Schellenberg R, et al. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ. 2001;322:134–7
  40. Schellenberg R, et al. Dose-dependent efficacy of the Vitex agnus-castus extract Ze 440 in patients suffering from premenstrual syndrome. Phytomedicine. 2012;19:1325– 1331 3.
  41. Berger D, et al. Efficacy of Vitex agnus-castus L. extract Ze 440 in patients with pre-menstrual syndrome (PMS). Arch Gynecol. Obstet. 2000;264:150-153.
  42. Koetter U, et al. A randomized, double blind, placebo-controlled, prospective clinical study to demonstrate clinical efficacy of a fixed valerian hops extract combination (Ze 91019) in patients suffering from non-organic sleep disorder. Phytother Res 2007;21(9):847-51.
  43. Notter D, et al. Efficacy and safety of a valerian-hops combination-preparation in different sleep disorders, a therapy observation. Phytotherapy. 2003;3:9-13.
  44. Füssel A, et al. Effect of a fixed valerian-hop extract combination (Ze 91019) on sleep polygraphy in patients with non-organic insomnia: a pilot study. Eur J Med Res. 2000;5:385–90.
  45. Lataster MJ, et al. The treatment of patients with sleep disorders. Notabene Medici. 1996;4:182.
  46. Brattström A. Scientific evidence for a fixed extract combination (Ze 91019) from valerian and hops traditionally used as a sleep-inducing aid. Wien Med Wochenschr. 2007;157(13-14):367-70.
  47. Morin CM, et al. Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial. Sleep. 2005 Nov 1;28(11):1465-71.
  48. Brattstrom A. Long-term effects of St. John’s wort (Hypericum perforatum) treatment: A 1-year safety study in mild to moderate depression. Phytomedicine 2009;16:277-83.
  49. Schrader E. Equivalence of St John’s wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol. 2000;15:61-8.
  50. Woelk H. Comparison of St John’s wort and imipramine for treating depression: a randomized controlled trial. BMJ 2000;321:536-9.
  51. Schrader E, et al. Hypericum treatment of mild-moderate depression in a placebo-controlled study. A prospective, double-blind, randomized, placebo-controlled, multicentre study. Hum Psychopharmacol 1998;13(3):163–9.
  52. Ruedeberg C, et al. Hypericum perforatum L.(St John’s wort) extract Ze 117 inhibits dopamine re-uptake in rat striatal brain slices. An implication for use in smoking cessation treatment? Phytother Res. 2010;24(2):249-51.
  53. Kientsch U, et al. St. John’s wort extract Ze 117 (Hypericum perforatum) inhibits norepinephrine and serotonin uptake into rat brain slices and reduces β-adrenoceptor numbers on cultured rat brain cells. Pharmacopsychiatry. 2001;34(Sup.1):56-60.
  54. Schuchardt J, et al. Intestinal absorption and factors influencing bioavailability of magnesium-an update. Current Nutrition & Food Science. 2017;13(4):260-78.
  55. Jeon SH, et al. Taurine increases cell proliferation and generates an increase in [Mg2+] i accompanied by ERK 1/2 activation in human osteoblast cells. FEBS letters. 2007 Dec 22;581(30):5929-34.
  56. Head KA. Taurine-monograph. Alt Med Rev. 2001;6(1):78-82.
  57. Magnesium. 2014.Nutrient reference values for Australia and New Zealand. Available from: https://www.nrv.gov.au/nutrients/magnesium

We invite you to explore the research further by registering or logging into our health professional website

Related Articles